von Willebrand factor in factor VIII concentrates protects against neutralization by factor VIII antibodies of haemophilia A patients
Authors:
- 12 July 2001
- journal article
- Published by Wiley in Haemophilia
- Vol. 7 (4) , 375-380
Abstract
We investigated the neutralization activity of factor VIII (FVIII) antibodies of 12 haemophilia A patients, acquired during treatment with plasma‐derived FVIII concentrates. All plasma samples, drawn in a clinically stable situation before any immunotolerance treatment, contained anti‐A2 domain and anti‐light‐chain FVIII antibodies. In nine patients’ plasmas, containing relatively high amounts of FVIII light‐chain antibodies (53–96%), a higher neutralization activity was found against recombinant FVIII concentrate (Recombinate) than against plasma‐derived von Willebrand factor (vWF)‐containing concentrate (Haemoctin SDH). No difference in neutralization of the two concentrates was found in two patients’ plasmas with almost equal content of FVIII light‐ and heavy‐chain antibodies, or one plasma with predominantly heavy‐chain antibodies. These results suggest that haemophilia A patients with relatively high amounts of FVIII light‐chain antibodies in plasma might benefit by infusion of FVIII concentrates containing vWF because vWF appears to have some protective effect on FVIII. This hypothesis should be tested by a clinical study.Keywords
This publication has 13 references indexed in Scilit:
- A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factorBlood, 2000
- Effect of von Willebrand Factor and Its Proteolytic Fragments on Kinetics of Interaction between the Light and Heavy Chains of Human Factor VIIIThrombosis Research, 1999
- Factor VIII Inhibitor Antibodies with C2 Domain Specificity Are Less inhibitory to Factor VIII Complexed with von Willebrand FactorThrombosis and Haemostasis, 1996
- Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparationsHaemophilia, 1996
- Common inhibitory effects of human anti‐C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factorBritish Journal of Haematology, 1995
- Inter‐individual variation in half‐life of infused recombinant factor VIII is related to pre‐infusion von Willebrand factor antigen levelsBritish Journal of Haematology, 1995
- Epitope specificity and functional characterization of factor VIII inhibitors1995
- Structure and function of Factor VIII1995
- Variable inactivation of human factor VIII from different sources by human factor VIII inhibitorsBritish Journal of Haematology, 1991
- Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over timeBlood, 1988